NCT06165380进行中（未招募）2 期
A Prospective, Multicenter, Phase II Study on the Efficacy and Safety of Cardenilimab Combined With Chemotherapy in the Conversion Therapy of Locally Advanced Esophageal Squamous Cell Carcinoma.
Li Zhang1 个研究点 分布在 1 个国家目标入组 43 人开始时间: 2023年10月23日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 43
- 试验地点
- 1
- 主要终点
- Objective Response Rate
研究概览
简要总结
The goal of this trial is to test the efficacy and safety of cardenilimab combined with chemotherapy in the conversion therapy of locally advanced unresectable esophageal squamous cell carcinoma.
type of study: clinical trial
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1. Sign written informed consent before implementing any trial-related procedures;
- •Male or female, age ≥18 years old;
- •Patients with histologically confirmed esophageal squamous cell carcinoma, diagnosed as cT4a, T4b, NXM0 according to the 8th edition of AJCC TNM staging, and assessed as initially unresectable by the surgeon;
- •Have not received any systemic treatment for the current disease in the past, including surgery, anti-tumor radiotherapy, chemotherapy/immunotherapy, etc.;
- •Patients who agree to undergo radical surgical treatment and are judged by the surgeon to have no contraindications to surgery
- •ECOG score 0-1 points;
- •Expected survival time >6 months;
- •With sufficient organ function, subjects must meet the following laboratory indicators:
- •Absolute neutrophil count (ANC) ≥1.5x109/L without using granulocyte colony-stimulating factor in the past 14 days;
- •Without blood transfusion in the past 14 days, platelets ≥100×109/L;
- •Hemoglobin >9g/dL without blood transfusion or erythropoietin use in the past 14 days;
- •Total bilirubin ≤1.5×upper limit of normal (ULN);
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are within ≤2.5×ULN
- •Serum creatinine ≤1.5×ULN and creatinine clearance (calculated using the Cockcroft-Gault formula) ≥60 ml/min;
- •Good coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 times ULN;
- •Euthyroid, defined as thyroid stimulating hormone (TSH) within the normal range. If baseline TSH is outside the normal range, subjects can also be enrolled if total T3 (or FT3) and FT4 are within the normal range;
- •Myocardial enzyme spectrum is within the normal range (if the researcher comprehensively judges that simple laboratory abnormalities without clinical significance are also allowed to be included);
- •Female subjects of childbearing potential should receive a urine or serum pregnancy test with a negative result within 3 days before receiving the first dose of study drug (Day 1 of Cycle 1). If a urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is required. Women of non-reproductive age were defined as at least 1 year postmenopausal, or had undergone surgical sterilization or hysterectomy;
- •If there is a risk of pregnancy, all subjects (regardless of male or female) need to use low annual failure rate during the entire treatment period until 120 days after the last dose of study drug (or 180 days after the last dose of chemotherapy drug). Contraceptive measures at 1%.
排除标准
- •Other malignant diseases diagnosed within 5 years before the first dose (excluding radical basal cell carcinoma of the skin, squamous epithelial carcinoma of the skin, and/or carcinoma in situ that has been radically resected);
- •Endoscopically known signs of active bleeding in the lesion;
- •Currently participating in interventional clinical research treatment, or have received other research drugs or used research equipment within 4 weeks before the first dose;
- •Have previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or another type of stimulating or synergistic inhibition of T cell receptors (including but not limited to CTLA-4, OX-40, CD137 etc.) drugs;
- •Have received systemic systemic treatment with Chinese patent medicines with anti-tumor indications or drugs with immunomodulatory effects (including thymosin, interferon, interleukin, except for local use to control pleural effusion) within 2 weeks before the first dose;
- •Active autoimmune disease that requires systemic treatment (such as the use of disease-modifying drugs, glucocorticoids, or immunosuppressants) has occurred within 2 years before the first dose. Replacement therapies (such as thyroxine, insulin, or physiological glucocorticoids for adrenal or pituitary insufficiency, etc.) are not considered systemic treatments;
- •Are receiving systemic glucocorticoid treatment (excluding nasal spray, inhaled or other local glucocorticoids) or any other form of immunosuppressive therapy within 7 days before the first dose of the study; Note: Physiological doses of glucocorticoids (≤10 mg/day of prednisone or equivalent) are allowed;
- •Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation;
- •People who are known to be allergic to the drugs used in this study;
- •Those with multiple factors that affect capecitabine (such as inability to swallow, intestinal obstruction, etc.);
- •Have not fully recovered from toxicity and/or complications caused by any intervention before initiating treatment (i.e., ≤Grade 1 or reaching baseline, excluding fatigue or alopecia);
- •Known history of human immunodeficiency virus (HIV) infection (i.e. HIV 1/2 antibody positive);
- •Untreated active hepatitis B (defined as HBsAg positivity and a detected HBV-DNA copy number greater than the upper limit of normal value in the laboratory of the research center);
- •Note: Hepatitis B subjects who meet the following criteria can also be enrolled:
- •The HBV viral load before the first dose is <2500 copies/ml (500 IU/ml), and the subject should receive anti-HBV treatment during the entire study chemotherapy drug treatment period to avoid viral reactivation.
- •Subjects with anti-HBc (+), HBsAg (-), anti-HBs (-) and HBV viral load (-) do not need to receive prophylactic anti-HBV treatment, but need to be closely monitored for viral reactivation
- •Subjects with active HCV infection (HCV antibody positive and HCV-RNA level higher than the lower limit of detection);
- •Get live vaccine within 30 days before the first dose (cycle 1, day 1); NOTE: Injectable inactivated virus vaccine for seasonal influenza is allowed within 30 days before the first dose; however, intranasal live attenuated influenza vaccine is not allowed
- •Pregnant or lactating women;
- •The presence of any serious or uncontrollable systemic disease, such as:
- •1) The resting electrocardiogram has major abnormalities in rhythm, conduction or morphology that are difficult to control with severe symptoms, such as complete left bundle branch block, second degree or higher heart block, ventricular arrhythmia or atrial fibrillation; 2) Unstable angina, congestive heart failure, New York Heart Association (NYHA) chronic heart failure grade ≥ 2; 3) Any arterial thrombosis, embolism or ischemia occurred within 6 months before selected treatment, such as myocardial infarction, unstable angina, cerebrovascular accident or transient cerebral ischemic attack; 4) Unsatisfactory blood pressure control (systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg); 5) There is a history of non-infectious pneumonia requiring glucocorticoid treatment within 1 year before the first dose, or there is currently clinically active interstitial lung disease; 6) Active pulmonary tuberculosis; 7) There is an active or uncontrolled infection that requires systemic treatment; 8) Clinically active diverticulitis, abdominal abscess, gastrointestinal obstruction exists; 9) Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis; 10) Poorly controlled diabetes (fasting blood glucose (FBG) >10mmol/L); 11) Those whose urine routine shows urine protein ≥++, and the 24-hour urine protein quantification is confirmed to be >1.0 g; 12) Patients with mental disorders and unable to cooperate with treatment;
- •Evidence of medical history or disease, abnormal treatment or laboratory test values that may interfere with the trial results, prevent the subject from fully participating in the study, or other circumstances that the researcher believes are not suitable for enrollment. The researcher believes that there are other potential risks and are not suitable for participation this research.
研究组 & 干预措施
Cardenilimab Combined With Chemotherapy
Experimental
干预措施: Cardenilimab Combined With Chemotherapy (Drug)
结局指标
主要结局
Objective Response Rate
时间窗: 2-5 years
The time from randomization to death from any cause.
次要结局
- Pathologic Complete Response(2-5 years)
- Progression-Free-Survival(2-5 years)
- Overall survival(2-5 years)
- Safety(2-5 years)
研究者
Li Zhang
Professor
Tongji Hospital
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast CancerTriple Negative Breast Cancer (TNBC)NCT05088057Aiping Shi30
招募中
不适用
Chemotherapy and Pelvic Hypofractionated Radiation Followed by Brachytherapy for Cervical CancerCervical CancerNCT04070976National Institute of Cancerología82
招募中
2 期
Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction AdenocarcinomaGastroesophageal Junction Adenocarcinoma (Siewert II-III)NCT06163729Cancer Institute and Hospital, Chinese Academy of Medical Sciences68
尚未招募
2 期
Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural MesotheliomaPleural MesotheliomaNCT06416930Cancer Institute and Hospital, Chinese Academy of Medical Sciences59
进行中（未招募）
2 期
A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast CancerCarcinoma Breast Stage IVNCT02755272Fox Chase Cancer Center87